Building in China - Study trip of the faculty of Civil Engineering of the HTWG Konstanz 2008

Im März 2008 führte die Fakultät Bauingenieurwesen der HTWG Konstanz eine studentische Exkursion nach China durch. Auf dem Programm standen interessante Baustellen Shanghai, Nanjing, Zhenjiang und Beijing sowie der Besuch von Hochschulen. Der Exkursionsbericht beschreibt die besuchten Bauvorhaben und gibt persönliche Eindrücke der Exkursionsteilnehmer wieder.In March 2008 the faculty of civil engineering of the University of Applied Sciences Konstanz, Germany, conducted a study trip for students of civil engineering to China. Construction sites and universities in Shanghai, Nanjing, Zhenjiang and Beijing have been visited. The report describes the places seen and reflects the personal impressions of the participants

Effects of different nutrient supply on metabolism and mammary immune response to an LPS challenge in early lactation of dairy cows.

Energy and nutrient deficiency in dairy cows in early lactation is considered to contribute to their increased susceptibility to mastitis. We have tested the hypothesis that feeding diets with high contents of either nitrogenic, glucogenic, or lipogenic components in early lactation affects both the endocrine and metabolic status, as well as the mammary immune competence. After calving, cows were fed increasing amounts of concentrate up to 10 kg/d rich in crude protein (nitrogenic, n = 10), glucogenic precursors (glucogenic, n = 11), or lipids (lipogenic, n = 11). In wk 3, one udder quarter was challenged with lipopolysaccharide (LPS) from Escherichia coli. Blood and milk were sampled on the day before LPS challenge (d -1), and on d 0, 1, 2, 3, and 9 after LPS challenge. On the day of LPS challenge additional samples were taken hourly for quarter milk and every 3 h for blood. Urea concentrations were higher in plasma and milk of cows fed the nitrogenic diet. However, plasma concentrations of glucose, cholesterol, triglycerides, β-hydroxybutyrate, nonesterified fatty acids, as well as insulin, glucagon, and insulin-like growth factor-1 were not affected by the different diets. The mammary immune challenge induced a substantial increase of somatic cell count (SCC) in the treated quarter, and a transient decrease of total milk yield and white blood cells similar in all diet groups for one day. The absolute phagocytosis of blood leukocytes was decreased; however, the phagocytosis per cell was increased in glucogenic-fed cows at 6 h after LPS challenge. During mammary inflammation an insulin resistance, shown by increased plasma glucose, insulin, and glucagon, developed similarly in all diet groups. β-hydroxybutyrate and nonesterified fatty acids were decreased at 1 d after LPS challenge in glucogenic-fed cows only. Cholesterol did not change, and triglycerides only decreased significantly in lipogenic-fed cows 6 h after challenge. On d 9 after LPS challenge, SCC and milk yield and metabolic factors were recovered in all groups. In conclusion, the endocrine and metabolic situation, and the immune response to intramammary LPS of dairy cows during early lactation was not substantially influenced by the elevated supply of nitrogenic, glucogenic, or lipogenic components due to the provided feed in this study

The German linguistic validation of the Ureteral Stent Symptoms Questionnaire (USSQ)

We developed and validated the German version of the Ureteral Stent Symptoms Questionnaire (USSQ) for male and female patients with indwelling ureteral stents. The German version of the USSQ was developed following a well-established multistep process. A total of 101 patients with indwelling ureteral stents completed the German USSQ as well as the validated questionnaires International Prostate Symptom Score (IPSS) or International Consultation on Incontinence Questionnaire (ICIQ) and the Short Form Health Survey (SF-36). Patients completed questionnaires at 1 and 2-4 weeks after stent insertion and 4 weeks after stent removal. Statistical analyses were performed to assess the psychometric properties of the questionnaire. The German version of the USSQ showed good internal consistency (Cronbach's alpha = .72-.88) and test-retest reliability [intraclass correlation coefficient (ICC) = .81-.92]. Inter-domain associations within the USSQ showed substantial correlations between different USSQ domains, indicating a high conceptual relationship of the domains. Except from urinary symptoms and general quality of life, German USSQ showed good convergent validity with the corresponding validated questionnaires. All USSQ domains showed significant sensitivity to change (p ae .001). The new German version of the USSQ proved to be a reliable and robust instrument for the evaluation of ureteral stent-associated morbidity for both male and female patients. It is expected to be a valid outcome measure in the future stent research

Long-term strategies for sustainable biomass imports in European bioenergy markets

Projections show that biomass will remain important for reaching future EU renewable energy targets. In addition to using domestic biomass, European bioenergy markets will also partly rely on imports of biomass, in particular in trade-oriented EU member states like the United Kingdom, the Netherlands, Belgium, and Denmark. There has been a lot of debate on the sustainability of (imported) biomass and how policy should deal with this. In this research, therefore, we defined long-term strategies for sustainable biomass imports in European bioenergy markets. We used the input of different stakeholders in our approach through focus-group discussions and a global survey, focusing on the following aspects: key principles of sustainable biomass trade, risks and opportunities of biomass trade, both for import regions (EU countries) and for sourcing regions, and practical barriers for trade. Overall we conclude that policies should be stable and consistent within a long-term vision. An overall sustainability assurance framework of biomass production and use is key, but should ultimately apply to all end uses of biomass. Furthermore, the mobilization of biomass should be supported, as well as commoditization, considering the large diversity of biomass. Side impacts of biomass use should be monitored. Reducing investors’ risk perception is crucial for future developments in the biobased economy, and a clear policy to phase out fossil fuels, e.g. through a carbon tax, needs to be implemented. The results of this research are of interest for policy makers when deciding on long-term strategies concerning sustainable bioenergy markets.</p

Long-term strategies for sustainable biomass imports in European bioenergy markets

Projections show that biomass will remain important for reaching future EU renewable energy targets. In addition to using domestic biomass, European bioenergy markets will also partly rely on imports of biomass, in particular in trade-oriented EU member states like the United Kingdom, the Netherlands, Belgium, and Denmark. There has been a lot of debate on the sustainability of (imported) biomass and how policy should deal with this. In this research, therefore, we defined long-term strategies for sustainable biomass imports in European bioenergy markets. We used the input of different stakeholders in our approach through focus-group discussions and a global survey, focusing on the following aspects: key principles of sustainable biomass trade, risks and opportunities of biomass trade, both for import regions (EU countries) and for sourcing regions, and practical barriers for trade. Overall we conclude that policies should be stable and consistent within a long-term vision. An overall sustainability assurance framework of biomass production and use is key, but should ultimately apply to all end uses of biomass. Furthermore, the mobilization of biomass should be supported, as well as commoditization, considering the large diversity of biomass. Side impacts of biomass use should be monitored. Reducing investors’ risk perception is crucial for future developments in the biobased economy, and a clear policy to phase out fossil fuels, e.g. through a carbon tax, needs to be implemented. The results of this research are of interest for policy makers when deciding on long-term strategies concerning sustainable bioenergy markets.</p

Sourcing overseas biomass for EU ambitions: assessing net sustainable export potential from various sourcing countries

Abstract Low‐cost sustainable biomass availability in the European Union may not be able to meet increasing demand; exploring the option of importing biomass is therefore imperative for the years to come. This article assesses sustainable biomass export potential from Brazil, Colombia, Indonesia, Kenya, Ukraine, and the United States by applying a number of sustainability criteria. Only biomass types with the highest potential are selected, to take advantage of economies of scale, e.g. pulpwood, wood waste, and residues in the United States, and agricultural residues in Ukraine. This study found that, except for the United States, pellet markets in the sourcing regions are largely undeveloped. The export potential depends strongly on pellet mill capacity and assumed growth rates in the pellet industry. Results show that the United States, Ukraine, Indonesia, and Brazil offer the highest biomass export potential. In the Business As Usual 2030 scenario, up to 204 PJ could potentially be mobilized; in the High Export scenario this could increase to 1423 PJ, with 89% of the potential being available for costs ranging from 6.4 to 15 €/GJ. These potentials meet the European Commission requirements for a 70% reduction in greenhouse gas emissions set in the Renewable Energy Directive. The total export potentials do not reflect the net possible import potentials to the European Union, as biomass could be imported to other countries where there is a demand for it, where less strict sustainability requirements are applied, and which are proximate to the sourcing regions, notably South Korea, Japan, and China. © 2018 The Authors. Biofuels, Bioproducts and Biorefining published by Society of Chemical Industry and John Wiley Sons, Ltd

Sourcing overseas biomass for EU ambitions: assessing net sustainable export potential from various sourcing countries

Abstract Low‐cost sustainable biomass availability in the European Union may not be able to meet increasing demand; exploring the option of importing biomass is therefore imperative for the years to come. This article assesses sustainable biomass export potential from Brazil, Colombia, Indonesia, Kenya, Ukraine, and the United States by applying a number of sustainability criteria. Only biomass types with the highest potential are selected, to take advantage of economies of scale, e.g. pulpwood, wood waste, and residues in the United States, and agricultural residues in Ukraine. This study found that, except for the United States, pellet markets in the sourcing regions are largely undeveloped. The export potential depends strongly on pellet mill capacity and assumed growth rates in the pellet industry. Results show that the United States, Ukraine, Indonesia, and Brazil offer the highest biomass export potential. In the Business As Usual 2030 scenario, up to 204 PJ could potentially be mobilized; in the High Export scenario this could increase to 1423 PJ, with 89% of the potential being available for costs ranging from 6.4 to 15 €/GJ. These potentials meet the European Commission requirements for a 70% reduction in greenhouse gas emissions set in the Renewable Energy Directive. The total export potentials do not reflect the net possible import potentials to the European Union, as biomass could be imported to other countries where there is a demand for it, where less strict sustainability requirements are applied, and which are proximate to the sourcing regions, notably South Korea, Japan, and China. © 2018 The Authors. Biofuels, Bioproducts and Biorefining published by Society of Chemical Industry and John Wiley Sons, Ltd

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

© 2016 Elsevier Ltd Background In a phase 2 study in patients with metastatic renal cell carcinoma, overall survival was associated with T-cell responses against IMA901, a vaccine consisting of ten tumour-associated peptides. In this phase 3 trial, we aimed to determine the clinical effect of adding IMA901 to sunitinib, the standard first-line treatment in metastatic renal cell carcinoma with postulated favourable immunomodulatory effects. Methods The IMPRINT study is an open-label, randomised, controlled, phase 3 trial done at 124 clinical sites in 11 countries. HLA-A*02-positive patients (aged ≥18 years) with treatment-naive, histologically confirmed metastatic or locally advanced (or both) clear-cell renal cell carcinoma were randomly assigned (3:2) to receive sunitinib plus up to ten intradermal vaccinations of IMA901 (4·13 mg) and granulocyte macrophage colony-stimulating factor (75 μg), with one dose of cyclophosphamide (300 mg/m2) 3 days before the first vaccination, or to receive sunitinib alone. Sunitinib (50 mg) was given orally once daily, with each cycle defined as 4 weeks on treatment followed by 2 weeks off treatment, until progression of disease as determined by the investigator, death, or withdrawal of consent. Block randomisation (block size five) was done centrally using an interactive web response system, stratified by prognostic risk, geographical region, and previous nephrectomy. Patients and investigators were not masked to treatment allocation. The primary endpoint was overall survival from randomisation until death of any cause as determined by the investigator, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01265901. Findings Between Dec 22, 2010, and Dec 15, 2012, we screened 1171 patients, of whom 339 were randomly assigned to receive sunitinib plus IMA901 (n=204) or sunitinib monotherapy (n=135). Patients had a median follow-up of 33·27 months (IQR 29·92–35·64). Median overall survival did not differ significantly between the groups (33·17 months [95% CI 27·81–41·36] in the sunitinib plus IMA901 group vs not reached [33·67–not reached] in the sunitinib monotherapy group; hazard ratio 1·34 [0·96–1·86]; p=0·087). 116 (57%) of 202 patients in the sunitinib plus IMA901 group and 62 (47%) of 132 in the sunitinib group had grade 3 or worse adverse events, the most common of which were hypertension, neutropenia, and anaemia in both groups, and mild-to-moderate transient injection-site reactions (eg, erythema, pruritus) were the most frequent IMA901-related side-effect in the sunitinib plus IMA901 group. Serious adverse events leading to death occurred in four (2%) patients (one respiratory failure and circulatory collapse [possibly related to sunitinib], one oesophageal varices haemorrhage [possibly related to sunitinib], one cardiac arrest [possibly related to sunitinib], and one myocardial infarction) and eight (6%) patients in the sunitinib group (one case each of renal failure, oesophageal varices haemorrhage, circulatory collapse, wound infection, ileus, cerebrovascular accident [possibly treatment related], and sepsis). Interpretation IMA901 did not improve overall survival when added to sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. The magnitude of immune responses needs to be improved before further development of IMA901 in this disease is indicated. Funding Immatics Biotechnologies